Tudor Financial Inc. Trims Holdings in Amgen Inc. $AMGN

Tudor Financial Inc. decreased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 36.8% in the second quarter, HoldingsChannel reports. The firm owned 9,784 shares of the medical research company’s stock after selling 5,697 shares during the quarter. Amgen makes up 1.6% of Tudor Financial Inc.’s investment portfolio, making the stock its 13th biggest position. Tudor Financial Inc.’s holdings in Amgen were worth $3,543,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Anfield Capital Management LLC increased its stake in shares of Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after buying an additional 70 shares during the period. Dogwood Wealth Management LLC lifted its stake in Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after acquiring an additional 55 shares during the period. Tower View Wealth Management LLC boosted its holdings in Amgen by 331.6% in the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 63 shares in the last quarter. Manning & Napier Advisors LLC increased its position in Amgen by 49.2% during the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after purchasing an additional 32 shares during the period. Finally, Evergreen Advisors LLC purchased a new position in Amgen during the 1st quarter valued at $37,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insider Buying and Selling at Amgen

In other Amgen news, SVP Rachna Khosla sold 1,252 shares of the firm’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $416.43, for a total transaction of $521,370.36. Following the completion of the sale, the senior vice president directly owned 6,404 shares in the company, valued at approximately $2,666,817.72. This trade represents a 16.35% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Nancy A. Grygiel sold 2,970 shares of Amgen stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the transaction, the senior vice president directly owned 7,340 shares of the company’s stock, valued at $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 6,222 shares of company stock worth $2,540,926 over the last three months. Corporate insiders own 0.85% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on AMGN. Robert W. Baird raised their target price on shares of Amgen from $215.00 to $230.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 5th. Truist Financial increased their price target on shares of Amgen from $340.00 to $362.00 and gave the stock a “hold” rating in a research note on Wednesday, August 5th. Weiss Ratings upgraded shares of Amgen from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, August 6th. Wall Street Zen raised Amgen from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Finally, Wells Fargo & Company upped their target price on Amgen from $390.00 to $400.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, thirteen have issued a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $380.43.

Amgen Stock Up 0.3%

NASDAQ:AMGN opened at $444.12 on Friday. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. The firm’s 50-day moving average price is $395.82 and its 200-day moving average price is $366.66. The company has a market capitalization of $240.11 billion, a PE ratio of 27.60, a P/E/G ratio of 3.19 and a beta of 0.43. Amgen Inc. has a 1-year low of $269.77 and a 1-year high of $447.03.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The company had revenue of $10.05 billion during the quarter, compared to analysts’ expectations of $9.43 billion. During the same period last year, the company posted $6.02 EPS. Amgen’s revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, equities analysts predict that Amgen Inc. will post 22.97 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be given a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Friday, August 21st. Amgen’s dividend payout ratio (DPR) is 62.65%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.